Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Elecoglipron

Drug and asset intelligence for Elecoglipron with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

AstraZeneca →

Recent signals(1)

ClinicalJune 26, 2026

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM

AstraZeneca is conducting two pivotal Phase III studies to evaluate the efficacy and safety of elecoglipron in adults with obesity or overweight, with and without T2DM.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

AstraZeneca — Elecoglipron

Key milestones include trial enrollment updates and interim results, which will indicate the potential for regulatory submissions.

June 26, 2026 · N/A

Indications

Therapeutic areas

Endocrinology →

Endocrinology · Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.